Author name: Rob Quinn

The world of specialty pharmaceuticals consistently brings forth groundbreaking therapies, bringing hope to patients suffering from previously incurable conditions. However, their success heavily depends on patient adherence. An in-depth examination of patient journeys indicates a concerning fact – a sizeable number of patients, prescribed these potentially life-saving specialty drugs, discontinue their treatment plans frequently before their […]

Specialty pharmacy distribution is changing as specialty drug treatments become more commonplace. Many biosimilars have entered the rare disease market, directly competing with biologics like Humira that represented breakthroughs in their time. New treatments for a wide range of conditions are also available, including biologics, cell and gene therapies for rare diseases.  Wider adoption of

Patients readily switch doctors, making medication adherence strategies difficult. Specialty pharmacy data can assist with the patient journey orchestration.